Double-Blind?

Baselineb and Change in PTSD Measure

Statistically Significant? (versus control)

Loss of Diagnosis or Clinical Improvement (%)

Principal Limitations

Yes

~75

 

Global improvement score 1 = very much improved, 2 = much improved

Dropout 33%, 38%, and 35% using LOCF

 

−39.6

Yes

 

−37.9

Yes

 

−25.3

 

 

 

62%

 

 

 

54%

 

 

 

37%

Yes

74.3, 73.2

 

<20 CAPS score = remission

Dropout ~38% and 40% using LOCF

 

−35.5

Yes

 

−24.7

30%

 

 

 

20%

Yes

~75

 

>30% decrease in CAPS-2 score and CGI-I of 1 or 2

Dropout 31% and 28% using LOCF

 

33

Yes

 

23.2

 

 

 

53%

 

 

 

32%

Yes

~108

 

Duke Global Rating

Dropout ~17% in one arm with a ~17% differential dropout; completer analysis only

 

−3

No

17%

 

−9

33%

Yes

Baseline NR Score of 1:

 

Responder (Duke cutoff of 1–2)

Dropout ~22% and ~42% with a 20% differential using LOCF

 

59%

Yes

85%

 

19%

 

62%

Yes

~82

 

N/A

Dropout ~36% and ~13% with a 23% differential and no handling of missing data

 

−35

Yes

 

 

−12

No

 

 

−17

 

 

−3

and not the maintenance phase, which only included patients who were “much improved” or “very much improved.”

dSeven dropped out before receiving study drug.

eAntidepressant.

fMartenyi (2002a) does not report actual dropout rates, only average length of treatment, which may be considered rough to completer rates, but it may conceal important information.

g23 patients total from a trauma clinic (TC).

h24 patients total from a VA site.

iData were reported by intake site: trauma clinic (nonveterans) and VA site.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement